Kiyoshi Takayama has received a Ph.D. in pharmaceutical science from the University of Tokyo. After his PhD he worked for more than 12 years as a research scientist at Taisho Pharmaceutical, Japan, where he was involved in the development of G-protein coupled receptors (GPCRs) assay and the conducting of various drug discovery programs for chronic inflammation and chronic obstructive pulmonary disease (COPD). In 2006, Kiyoshi left Taisho and founded NB Health Laboratory, a technology platform company for the generation of functional mAbs targeting GPCRs. NB Health Laboratory is pioneering a new field in GPCR-targeted drug discovery by targeting GPCRs for lipid mediator ligands using monoclonal antibodies.